Purchase this article with an account.
J. S. Bryan, M. D. Bennett, C. S. Otto, H. A. Williams; Intravitreal Moxifloxacin Combined With Bevacizumab (Avastin®) for Macular Edema Secondary to Branch and Central Retinal Vein Occlusions. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2687.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate whether intravitreal Moxifloxacin combined with Avastin might have a positive biologic effect in the treatment of Macular edema associated with branch and central retinal vein occlusions (BRVO and CRVO).
Seventeen BRVO patients and eleven CRVO patients with macular edema were enrolled. Patients received the moxifloxacin/Avastin intravitreal combination at 6 weekly intervals at the discretion of the investigator. The primary endpoint is the incidence and severity of adverse events. Secondary endpoints include changes in the following measures from baseline to months 6 and 12: best-corrected ETDRS visual acuity, central retinal thickness and macular edema as assessed by optical coherence tomography (OCT), and extent of edema as assessed by fluorescein angiography (FA).
To date, the patients enrolled in this study have demonstrated no adverse events. Preliminary visual results demonstrated an average acuity improvement of 23.2 letters in the BRVO group and 19.4 letters in the CRVO group. Dosing varied from one to six intravitreal injections. OCT and FA both demonstrated a reduction in edema. Twelve-month data will be presented.
Clinical Trial: :
This PDF is available to Subscribers Only